Investigation of the impact of patient satisfaction with subcutaneous injection of Bulevirtide on therapy response in Hepatitis B/D co-infection

Investigation of the impact of patient satisfaction with subcutaneous injection of Bulevirtide on therapy response in Hepatitis B/D co-infection - PROs during therapy with bulevirtide

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033153

Enrollment

114

Registered

2023-12-11

Start date

2024-01-02

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B17.0

Interventions

Group 1: Hepatitis D patients undergoing Bulevirtide therapy fill out a patient questionnaire at their next scheduled appointment with their treating physician. The response to therapy is assessed bas

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - age = 18 years - written informed consent - HBV/HDV coinfection - therapy with bulevirtide - at least three visits during bulevirtide therapy

Exclusion criteria

Exclusion criteria: - age < 18 years - missing written informed consent

Design outcomes

Primary

Measure	Time frame
Prospective assessment of patient satisfaction	—

Secondary

Measure	Time frame
Correlation with virological and biochemical treatment response	—

Countries

Germany

Contacts

Public ContactJohannes Wiegand

Universitätsklinikum Leipzig

johannes.wiegand@medizin.uni-leipzig.de+493419712330

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026